InterventionsHumans

Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk

ADA Scientific Sessions 2025 Abstract

The paper

Urja N Kalathiya, Jeph S. Herrin, Kavya Sindhu Swarna,

Joshua J. Neumiller, Rodolfo J. Galindo, Guillermo E. Umpierrez, Joseph S. Ross, Yihong Deng, Eric C. Polley, Mindy M. Mickelson,

Rozalina Grubina McCoy

Baltimore

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Poster 780-P

doi.org/10.2337/db25-780-p

SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026